ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual,
Chapter 2 - Immunization Program

All Sections of the Immunization Manual

Due to the migration of the BCCDC website to a new platform, many of the web address links contained within the Immunization Manual were broken.

These links have been corrected online and multiple pages within the Immunization Manual have been revised solely to update web address links. Please remove the following pages and replace with the updated pages:

Section IA - Introduction
Page number: 1, 3, 6, 7, 42, 43. Please remove page 44.

Section IB - Informed Consent
Page number: 6, 7, 12, 15, 16

Section III – Immunization of Special Populations
Page number: 17, 18a, 37, 45, 54

Section IV - Administration of Biological Products
Page number: 1, 2, 2a, 19, 20, 23, 24

Section IVB - Reducing Immunization Injection Pain
Page number: 19, 24, 25

Section V - Management of Anaphylaxis in a Non-Hospital Setting
Page number: 3, 10, 13

Section VI - Management of Biologicals
Page number: 3, 4, 6, 8, 12, 23, 24

Section VIII - Principles of Immunology
Page number: 22

Section IX - Adverse Events Following Immunization
Page number: 2, 4, 4a, 16, 18, 34, 38-43
Section VII – Biological Products

Meningococcal Quadrivalent Polysaccharide Vaccine (Groups A, C, Y, W-135)
MENOMUNE®

This page has been removed.

The rationale for the discontinued use of MENOMUNE® in BC is as follows:

- With introduction of now three conjugate quadrivalent meningococcal vaccines in Canada, demand for quadrivalent meningococcal polysaccharide vaccine (MENOMUNE® - A/C/Y/W-135) has declined dramatically.
- While this product is the only quadrivalent meningococcal vaccine with an age indication for use in older adults, with the three conjugates all having age indications only up to 55 years of age in Health Canada approved product monographs, the National Advisory Committee on Immunization has recommended that any of the three conjugate products may be used if required in adults older than 55 years.
- While BCCDC has continued to maintain a small stock of MENOMUNE® - A/C/Y/W-135 for use in those with a contraindication to a conjugate vaccine, a review of the components of the products indicates that the only potential allergens in the conjugate vaccines are the carrier proteins, which are highly unlikely to be known allergens in any given individual (see table below). Should the need arise to obtain a different vaccine for any one individual with a known hypersensitivity, an alternate conjugate quadrivalent vaccine could be obtained for use.
- The supply of MENOMUNE® - A/C/Y/W-135 has been interrupted with no stock available until early 2016 at the earliest, and updating our immunization guidelines to the use of the conjugate products with reliable supply streams because of routine demand for other larger programs (e.g., school based immunization) provides better security of supply.

Potential Allergens in Meningococcal A, C, Y, W-135 Conjugate Vaccines

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Potential Allergens</th>
</tr>
</thead>
<tbody>
<tr>
<td>Menomune®</td>
<td>Thimerosal (multi-dose vials only), latex (vial stopper)</td>
</tr>
<tr>
<td>Menactra®</td>
<td>Diphtheria toxoid protein</td>
</tr>
<tr>
<td>Menevo™</td>
<td>Diphtheria CRM197 protein</td>
</tr>
<tr>
<td>Nimenrix®</td>
<td>Tetanus toxoid protein</td>
</tr>
</tbody>
</table>

Please remove page number: 43 dated June 2015
Please add new page number: 43 dated December 2015

Please also remove the Table of Contents for Section VII – Biological Products dated September 2015 and replace with the enclosed updated Table of Contents dated December 2015.
If you have any questions or concerns, please contact Christine Halpert, Senior Practice Leader, BCCDC at telephone (604) 707-2555, fax (604) 707-2515 or by email at Christine.halpert@bccdc.ca.

Sincerely,

Monika Naus, MD MHSc FRCPC FACPM
Medical Director
Immunization Programs and Vaccine Preventable Diseases Service
BC Centre for Disease Control

pc: BC Ministry of Health:
Dr. Perry Kendall
Provincial Health Officer

Dr. Bonnie Henry
Deputy Provincial Health Officer

Craig Thompson
Director of Immunization
Healthy Populations and Development Branch

Warren O’Briain
Executive Director
Healthy Populations and Development Branch